Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome
AbstractAdipose tissue-derived serine protease inhibitor (vaspin), which has endocrine and local roles in atherosclerosis growth, is also synthesized by adipose tissue; it was found that vaspin was negatively correlated with blood pressure in obese patients, while vaspin levels were decreased in endothelial dysfunction. The aim of the present study was to determine rosuvastatin modulation effects on serum vaspin levels in acute coronary syndrome (ACS) with class I obesity. A total number of seventy patients with acute coronary syndrome previously and currently treated with rosuvastatin was compared to 40 patients with IHD not treated by rosuvastatin as a control. Vaspin serum levels were higher in rosuvastatin-treated patients with acute coronary syndrome compared to the patients with acute coronary syndrome not treated by rosuvastatin, p < 0.01. Additionally, in the rosuvastatin-treated group, patients with STEMI showed higher vaspin serum levels compared to NSTEMI p < 0.01. Conclusion: Rosuvastatin significantly increases vaspin serum levels in acute coronary syndrome. View Full-Text
Share & Cite This Article
Al-kuraishy, H.M.; Al-Gareeb, A.I.; Al-Buhadilly, A.K. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases 2018, 6, 9.
Al-kuraishy HM, Al-Gareeb AI, Al-Buhadilly AK. Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome. Diseases. 2018; 6(1):9.Chicago/Turabian Style
Al-kuraishy, Hayder M.; Al-Gareeb, Ali I.; Al-Buhadilly, Ali K. 2018. "Rosuvastatin Improves Vaspin Serum Levels in Obese Patients with Acute Coronary Syndrome." Diseases 6, no. 1: 9.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.